IMNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immunome Inc (IMNM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, positive trial results, and upcoming NDA filing in Q2 2026 position it well for future growth. Despite short-term technical weakness and financial challenges, the long-term potential outweighs the risks.
The technical indicators show a neutral to slightly bearish trend. The MACD is negative and contracting, the RSI is neutral at 36.915, and moving averages are converging. The stock is trading near its support level of 21.358, with resistance at 23.677. Short-term price movement is expected to be limited.
Strong analyst ratings with price targets ranging from $32 to $40, indicating significant upside potential.
Positive Phase 3 trial results for varegacestat, with high approval likelihood and a potential $1B-$2B market opportunity.
Redmile Group's increased stake in the company, reflecting institutional confidence.
Upcoming NDA filing in Q2 2026, which could boost valuation upon approval.
Weak financial performance in Q3 2025, with revenue dropping to zero and negative EPS of -0.
Short-term technical indicators suggest limited upside in the near term.
Lack of recent congress trading data, which could have provided additional confidence.
In Q3 2025, Immunome reported zero revenue (-100% YoY), a net income loss of $57.46M (improved by 21.99% YoY), and an EPS of -0.65 (down 16.67% YoY). Gross margin remained at 100%. While financials are weak, the company is in a development phase, focusing on its pipeline.
Analysts are highly optimistic about Immunome, with multiple firms raising price targets to $32-$40 and maintaining Buy or Outperform ratings. Positive trial results and the potential for varegacestat to dominate its market are key drivers of this sentiment.
